Core Insights - New analyses indicate that dementia with Lewy bodies (DLB) patients with lower plasma pTau181 levels experienced greater clinical benefits from neflamapimod in a Phase 2b clinical trial, suggesting a potential to target the underlying disease biology [1][2][5] - The findings support the company's patient enrichment strategy and dosing regimen for the upcoming Phase 3 trial [1][2] Clinical Trial Details - The RewinD-LB Phase 2b trial included an initial randomized phase comparing neflamapimod to placebo, followed by a neflamapimod-only extension phase [3][10] - In the initial phase, participants did not achieve expected plasma drug concentration levels, resulting in no statistically significant improvement on the primary endpoint [3][4] - The extension phase with a new batch of capsules (DP Batch B) showed statistically significant and clinically meaningful slowing of clinical progression compared to the initial batch [4] Treatment Response and Biomarkers - Treatment response increased progressively across DLB patient subgroups with lower plasma pTau181 levels, indicating a higher likelihood of patients without Alzheimer's disease (AD) co-pathology [2][5] - The analyses revealed a strong association between neflamapimod response and the absence of AD co-pathology, reinforcing confidence in the drug's potential to slow disease progression [2][5] Statistical Findings - Within-participant comparisons showed that at the lowest plasma pTau181 levels (<21 pg/mL), the average change in Clinical Dementia Rating Sum of Boxes (CDR-SB) was -1.11, indicating significant clinical improvement [6][7] - The mean change in the Alzheimer's Disease Cooperative Study — Clinical Global Impression of Change (ADCS-CGIC) score also demonstrated a greater effect at lower pTau181 levels [7][8] Future Plans - The company plans to initiate a global Phase 3 trial in the second half of 2026, focusing on patients with DLB enriched for those without AD co-pathology [16] - The planned trial will utilize a pTau181 cut-off level of <21 pg/mL, estimated to include 80% to 90% of patients without AD co-pathology [8][16]

Core Viewpoint - CervoMed has received FDA feedback that aligns with its proposed Phase 3 clinical trial design for neflamapimod, a drug targeting dementia with Lewy bodies (DLB), marking a significant step towards a potential New Drug Application submission [1][4] Phase 3 Trial Design and Regulatory Alignment - The Phase 3 trial will be a global, randomized, double-blind, placebo-controlled study involving approximately 300 DLB patients, set to begin in the second half of 2026 [2] - Patients with historical evidence of Alzheimer's disease will be excluded, and further enrichment will be achieved through a validated blood plasma test [2] - Participants will be randomized 1:1 to receive either neflamapimod or placebo for 32 weeks, followed by an additional 48-week extension with neflamapimod only [2] Primary and Secondary Endpoints - The primary endpoint will be the change in the Clinical Dementia Rating-Sum of Boxes (CDR-SB), consistent with the recently completed Phase 2b trial [3] - Secondary endpoints will include the percentage of participants with a greater than 1.5-point increase in CDR-SB and other established cognitive and motor function measures [3] Advancing Toward Registration - CervoMed's CEO expressed satisfaction with the FDA's alignment on the trial design, emphasizing the potential of neflamapimod to transform care for DLB patients [4] - The company anticipates feedback from other global regulators and plans to provide further details on the Phase 3 trial design in early 2026 [4] About Dementia with Lewy Bodies - DLB is the second most common progressive dementia after Alzheimer's disease, affecting millions globally, with no approved treatments available in the U.S. or EU [5] About Neflamapimod - Neflamapimod is an investigational oral drug that inhibits a key enzyme involved in neuroinflammation and synaptic dysfunction, showing promise in restoring synaptic function and improving neuron health [6][7] - Clinical trials have demonstrated that neflamapimod is generally well tolerated and has shown efficacy in improving dementia severity and functional mobility in DLB patients [8]